An Ascending Single Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics / Pharmacodynamics Of PF-05280602, A Recombinant Factor VIIa Variant (813d), In Adult Hemophilia A And B Subjects With Or Without Inhibitors

Trial Profile

An Ascending Single Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics / Pharmacodynamics Of PF-05280602, A Recombinant Factor VIIa Variant (813d), In Adult Hemophilia A And B Subjects With Or Without Inhibitors

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Apr 2017

At a glance

  • Drugs Marzeptacog alfa (Primary)
  • Indications Haemophilia A; Haemophilia B
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors Catalyst Biosciences
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Jun 2015 According to a Catalyst Biosciences media release, positive results from this study were presented at the 2015 International Society on Thrombosis and Haemostatsis (ISTH) Meeting.
    • 16 Jun 2015 Preliminary results will be presented at the 2015 International Society on Thrombosis and Haemostatsis Meeting, according to a Catalyst Biosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top